NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
Clinical Trials
13 trialsNCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT04521361 2025-09-19
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
Bayer
Phase 1 Completed
NCT03076203 2025-04-29
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
Thomas Jefferson University
Phase 1 Completed
NCT03996473 2024-10-10
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Bayer
Phase 1 Terminated
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02814669 2019-09-24
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Hoffmann-La Roche
Phase 1 Completed
NCT01798108 2017-05-19
Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases
Bayer
Phase 1 Completed
NCT02442063 2016-11-30
Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions
Bayer
Phase 1 Completed
NCT01565746 2016-10-17
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Bayer
Phase 1 Completed
NCT00667537 2015-12-14
PK in Pts With HRPC & Skeletal Metastes
Bayer
Phase 1 Completed
NCT02396368 2015-11-20
Radium-223
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Withdrawn
NCT00748046 2014-06-25
Alpharadinâ„¢ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
Bayer
Phase 1 Completed